The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting, according to a new study.

Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and obesity. Also known as GLP-1 agonists, these drugs work by mimicking a ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...